3StocksOnFire — US Stock Trading Community · 451+ trades · 257% returns · 15,000 members · Main Site · Trader's Guide · Articles · Video Analyses
3 Stocks On Fire
3StocksOnFire Community Forum
Home Message Boards Trader's Guide Articles Video Analysis About Us Search Register

News:

Welcome to 3StocksOnFire! US stock trading community (2005-2010) with 451+ documented trades and 15,000+ members. View Portfolios | Stock Articles | Quotes

Main Menu

OSCI - Momentum Alert

Started by Ramsburg, August 04, 2006, 11:08:02 AM

Previous topic - Next topic

Ramsburg


Not a trading draft, this is more like a watch list alert.

OSCI is gaining a lot of momentum right now, up 10 cents while I was getting to post this ;)
Frederick Ramsburg
www.3stocksonfire.org

Try our Premium Service or just Register a FREE Account

njshiva

WOW!! up 24%. :o
Great pick Ramsburg

Ramsburg

Quote from: njshiva on August 04, 2006, 05:42:48 PM
WOW!! up 24%. :o
Great pick Ramsburg

Thanks njshiva,

Unfortunately not in time to be an official pick for the portfolio, but still a great intraday ride...

I still see some potential for OSCI, probably the $1.70 resistance level or the ema-200 are the target of this rebound. Volume has been quite impressive too.

Regards,
Frederick Ramsburg
www.3stocksonfire.org

Try our Premium Service or just Register a FREE Account

njshiva

scient Pharma 2Q Loss Widens To $23M; DOJ Clears Buy
Dow Jones Newswires - August 08, 2006 11:58 AM ET

Related Quotes
Symbol         Last    Chg
OSCI    Trade    1.15    -0.07
Real time quote.

DOW JONES NEWSWIRES

Oscient Pharmaceuticals Corp.'s (OSCI) second-quarter loss widened to $23 million from $21.7 million a year earlier.

On a per-share basis, the company's loss narrowed to 25 cents from a loss of 28 cents, as average shares outstanding rose to 94 million from 76 million.

Analysts surveyed by Thomson First Call had, on average, predicted a loss of 26 cents a share.

Oscient, a biopharmaceutical company, recorded total revenue of $4.55 million, up from $4.24 million.

Oscient also said it expected its recently announced acquisition of Antara, a cardiovascular drug, to reduce seasonal fluctuations in the company's revenue. The company announced it had been granted early antitrust clearance by the Department of Justice for this acquisition.

Shares of Oscient Pharmaceuticals recently traded at $1.07, down 15 cents, or 12.3%

njshiva

looks like too many threads on OSCI.
HUGE volume we got here  ;)